US · PMN
ProMIS Neurosciences, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Toronto, ON M4S 3E2
- Website
- promisneurosciences.com
Price · as of 2024-12-31
$11.01
Market cap 30.74M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $375.00 | $396.77 | $0.00 | $0.00 | $51.30 |
| 2011 | $315.00 | $11,740.07 | $15,647.34 | $0.00 | $0.00 |
| 2012 | $675.00 | $667.11 | $0.00 | $0.00 | $4,296.60 |
| 2013 | $450.00 | $3,633.31 | $0.00 | $0.00 | $1,511.80 |
| 2014 | $435.00 | $3,830.41 | $14.47 | $0.00 | $0.00 |
| 2015 | $75.00 | $3,718.53 | $0.00 | $0.00 | $1,173.00 |
| 2016 | $210.00 | $478.79 | $0.00 | $0.00 | $1,204.10 |
| 2017 | $510.00 | $778.34 | $0.00 | $0.00 | $0.00 |
| 2018 | $390.00 | $332.71 | $0.00 | $0.00 | $2,791.20 |
| 2019 | $210.00 | $119.23 | $0.00 | $0.00 | $0.00 |
| 2020 | $165.00 | $1,310.73 | $0.00 | $0.00 | $0.00 |
| 2021 | $150.00 | $358.37 | $0.00 | $0.00 | $0.00 |
| 2022 | $112.50 | $234.04 | |||
| 2023 | $47.50 | ||||
| 2024 | $19.00 |
AI valuation
Our deep-learning model estimates ProMIS Neurosciences, Inc.'s (PMN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $11.01
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PMN | ProMIS Neurosciences, Inc… | $11.01 | 30.74M | — | — | — | — | 7.09 | 1.19 | — | 2.23 | — | 1.19 | 0.00% | — | — | 27.46% | 589.07% | 17.08% | 0.00 | -219.18 | 8.52 | 6.04 | -4.65 | -10775.00% | — | 15067.00% | -137.99% | -12.25 | 951.55% | 0.00% | 0.00% | 3.52% | -0.38 | -0.23 | — | -3.71 |
| ANL | Adlai Nortye Ltd. | $7.86 | 245.52M | +169% | — | — | — | -0.47 | 0.97 | — | 0.19 | — | 0.97 | 0.00% | — | — | -98.90% | -2580.88% | -51.49% | 1.07 | -28.22 | 1.41 | 1.37 | 0.70 | -6829.00% | -10000.00% | -855.00% | -211.30% | -1.14 | -2444.23% | 0.00% | 0.00% | 0.00% | 0.17 | 0.17 | — | -10.34 |
| BRTX | BioRestorative Therapies,… | $0.23 | 2.03M | +18,797% | +1,222% | — | — | -1.34 | 1.41 | 30.01 | -0.11 | — | 1.52 | 93.00% | -2881.59% | -2239.25% | -96.89% | 745.38% | -72.15% | 0.00 | — | 2.97 | 2.91 | 0.05 | -5304.00% | 17503.00% | 2629.00% | -69.27% | -2.20 | 537.75% | 0.00% | 0.00% | 0.00% | -0.11 | -0.16 | 3.25 | -18.17 |
| EDSA | Edesa Biotech, Inc. | $2.20 | 18.37M | — | — | — | — | -1.39 | 0.80 | — | 0.11 | — | 0.95 | 0.00% | — | — | -99.57% | -603.13% | -82.86% | 0.00 | — | 10.67 | 10.60 | 1.53 | -3420.00% | — | 4973.00% | -73.29% | -6.79 | -558.20% | 0.00% | 0.00% | 97.84% | 0.10 | 0.11 | — | -2.27 |
| ERNA | Ernexa Therapeutics Inc. | $0.29 | 2.24M | +35,680% | +510% | — | — | -2.77 | 72.62 | 212.25 | -3.39 | — | -360.15 | 83.51% | -2693.13% | -7652.75% | -2264.31% | -84.37% | -163.74% | 0.40 | -2.32 | 0.80 | 0.74 | 0.03 | -6152.00% | 75588.00% | -2067.00% | -13.12% | -5.39 | -87.22% | 0.00% | 0.00% | 28.59% | -7.81 | -7.56 | 210.46 | -50.59 |
| GOVX | GeoVax Labs, Inc. | $1.60 | 1.62M | — | +969% | — | — | -0.35 | 1.76 | 2.24 | -0.14 | — | 1.78 | 97.59% | -635.83% | -631.98% | -462.31% | 4381.85% | -286.62% | 0.00 | -1176.34 | 2.55 | 1.98 | 0.22 | -5284.00% | — | -209.00% | -278.43% | -7.94 | 4303.75% | 0.00% | 0.00% | 0.00% | -0.13 | -0.14 | 0.85 | -29.47 |
| LPCN | Lipocine Inc. | $9.96 | 55.3M | +2,939% | -66% | -60% | — | 2199.00 | 0.87 | 1.64 | 2.93 | — | 0.87 | 100.00% | -10.31% | 0.07% | 0.04% | 92.79% | 0.04% | 0.00 | — | 14.75 | 14.38 | 5.57 | -9995.00% | -49280.00% | -8896.00% | -7.14% | -0.81 | 113.94% | 0.00% | 0.00% | 7.81% | 2.83 | 2.49 | -0.29 | -3.70 |
| MPLT | MapLight Therapeutics, In… | $17.27 | 13.63M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | -83.21% | -1592.67% | -67.96% | 0.06 | — | 7.20 | 6.83 | 0.41 | 3955.00% | — | 5168.00% | — | -4.95 | -1528.13% | — | 0.00% | — | — | — | — | — |
| OSRH | OSR Holdings, Inc. | $0.41 | 10.58M | — | — | — | — | -5.08 | -1.58 | — | -3.39 | — | -1.58 | 0.00% | — | — | -15.54% | -21.87% | -10.39% | -0.27 | 81.95 | 0.07 | 0.01 | -0.48 | -85209.00% | — | 16722.00% | -21.32% | -0.33 | -15.79% | 0.00% | 0.00% | 0.00% | -3.39 | -5.47 | — | -12.68 |
| THAR | Tharimmune, Inc. | $5.12 | 202.4M | — | — | — | — | -0.16 | 1.51 | — | 0.13 | — | 1.51 | 0.00% | — | — | -233.69% | 613.15% | -166.32% | 0.00 | -908.64 | 1.54 | 1.47 | 0.29 | -9121.00% | — | 4934.00% | -553.30% | -4.52 | 537.61% | 0.00% | 0.00% | 0.00% | 0.13 | 0.15 | — | -24.00 |
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
- CEO
- Neil K. Warma
- Employees
- 7
- Beta
- -0.09
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $11.01) − 1 = — (DCF, example).